FDA Greenlights Roche's Tecentriq Combined with Lurbinectedin as Initial Maintenance Treatment for Advanced Small Cell Lung Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 03 2025
0mins
Should l Buy ?
Source: Yahoo Finance
FDA Approval: The FDA has approved the combination of Tecentriq® (atezolizumab) and lurbinectedin (Zepzelca®) for the first-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC), marking it as the first and only therapy of its kind for this aggressive disease.
Clinical Efficacy: The combination therapy demonstrated a 46% reduction in the risk of disease progression or death and a 27% reduction in the risk of death compared to Tecentriq alone, with median overall survival increasing from 10.6 months to 13.2 months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
